<DOC>
	<DOCNO>NCT02418598</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy intra-putaminal infusion AAV-hAADC-2 ( adeno-associated virus encode human aromatic L-amino acid decarboxylase ) stereotaxic surgery patient advance Parkinson 's disease .</brief_summary>
	<brief_title>AADC Gene Therapy Parkinson 's Disease</brief_title>
	<detailed_description>Subjects hospitalize conducted baseline examination Day -10 . The target putamen AAV-hAADC-2 infusion identify MRI image take prior operation , subject bilaterally infused total volume 200 / 600 µL total 4 site ( 2 site leave putamen , 2 site right putamen ; 50 / 150 µL per site ) flow rate 3 µL per minute Day 0 . After infusion complete , cannula device remove , surgical incision seam accordance usual trephination . After , cranial CT scan perform confirm whether complication occurrence intracranial bleeding . Subjects stay hospital 14 day infusion AAV-hAADC-2 . Data Safety Monitoring Board ( DSMB ) evaluate safety efficacy subject 6 month later assessment low dose cohort . If event relevant discontinuance criterion moderate severe adverse event casual relationship , `` Definitely related '' `` Possibly relate '' , AAV-hAADC-2 cohort , study move high dose cohort . At time 6 month infusion , investigator ass treatment effect AAV-hAADC-2 basis subject diary , clinical assessment levodopa requirement dosage . At time , investigator ass relationship dose AAV-hAADC-2 infused amount intra-putaminal expression FMT-PET imaging . The investigator also assess safety 5 year baseline examination . Long-term follow study additionally conduct 10 year reference guideline FDA .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dopa Decarboxylase</mesh_term>
	<criteria>1 . Patients idiopathic Parkinson 's disease meet diagnostic criterion Specified Disease designate Ministry Health , Labour Welfare ( 1995 ) : Research Committee CNS Degenerative Disease , LDopa effective early disease stage finding suggestive CNS Degenerative Disease find . 2 . Age ≤ 75 year time medical treatment . 3 . Age onset ≥ 35 year . 4 . Duration Ldopa therapy ≥ 5 year . 5 . Hoehn Yahr Stage IV OFF state onset medical treatment . 6 . Movement Disorder Societysponsored revision Unified Parkinson 's Disease Scale Part III ( MDSUPDRSIII ) , minimum motor score 30 maximum motor score 100 OFF state . 7 . Positive response dopaminergic therapy evidence remarkable improvement MDSUPDRSIII motor score define `` OFF '' `` ON '' state : minimum 16 point improvement MDSUPDRSIII dopaminergic therapy . 8 . Patients undergo stereotaxic surgery Parkinson 's disease due intolerable motor complication minimum score 4 maximum score 9 MDSUPDRSIV part B ( diurnal fluctuation symptom ) , responsive optimal medical therapy . 9 . To able comply requirement , include frequent clinical examination medical treatment , study . 10 . To keep therapeutic medicine Parkinson 's disease least 2 month prior participation study . 11 . Written informed consent . 1 . Patients suspect secondary / atypical parkinsonism base medical history cerebral vascular disease , exposure antipsychotic toxic agent , encephalitis base symptom Progressive supranuclear palsy , Pyramidal tract sign , autonomic sign , Dementia , Hallucination , Delusion base find magnetic resonance imaging ( MRI ) Lacunar infarct atrophy midbrain tectum atrophy pons cerebellum . 2 . Patients history 3 hour intensive violent dyskinesia past 6 month . 3 . Patients previous stereotaxy Parkinson 's disease ( pallidotomy , thalamotomy , deep brain stimulation ) . 4 . MiniMental State Examination ( MMSE ) ≤ 20 patient diagnosis dementia neuropsychological evaluation . 5 . Patients medical history Hallucination , Delusion , schizophrenia affective disorder within 6 month inform consent . 6 . Patients history significant cardiovascular disease include cerebrovascular accident . 7 . Malignant neoplasm brain , clinically significant neurological disease ( example significant brain atrophy consistent age ) . 8 . History malignancy , exception treat carcinoma cutaneum , within 5 year . 9 . Uncontrolled hypertension : systolic blood pressure ≥ 160 mmHg . 10 . Coagulopathy need anticoagulant therapy . 11 . Clinically significant immune dysfunction ( example , case require use immunosuppressive drug ) . 12 . Geriatric Depression Scale ( GDS ) short scale ≥ 10 point , antidepressant , score &gt; 5 point . 13 . On monoamine oxidase ( MAO ) A inhibitor , antipsychotic medication . 14 . Unable scan MRI . 15 . Cases without abnormal find FMTPET . 16 . Premenopausal female male desire impregnate female ( exclude : case sperm cryopreserved prior gene therapy child bear use sperm ) . 17 . Past medical history convulsive seizure within 3 year receive antiepileptic drug patient epileptic aberrance electroencephalography . 18 . Past medical history serious drug allergy . 19 . Patients participate clinical trial within 6 month . 20 . Patients meet follow criterion : 1 . Serious renal disorder ( Cr ≥ 2.0 mg/dl BUN ≥ 25mg/dl ) 2 . Serious hepatic disorder ( AST ( GOT ) / ALT ( GPT ) ≤2.5xupper limit normal ( ULN ) 3 . Serious diabetes ( casual blood glucose fast blood glucose ≥ 200 mg/dl HbA1c ≥ 9 % ) 21 . Any patient judge investigator inappropriate subject study .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Adeno-associated virus</keyword>
	<keyword>Aromatic L-amino acid decarboxylase</keyword>
	<keyword>AAV-hAADC-2</keyword>
	<keyword>AAV-2</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Gene Transfer</keyword>
	<keyword>Parkinson Disease</keyword>
	<keyword>Basal Ganglia Disease</keyword>
	<keyword>Brain Disease</keyword>
</DOC>